Assisting Smokers to Switch to a JUUL E-Cigarette by Devaluing Combustible Cigarettes

NCT04188197 | Completed Results

• 1 other identifier: RECON
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 2

Brief Summary

This study will evaluate a reward devaluation strategy in which smokers use the JUUL e-cigarette immediately before any combustible cigarettes (CCs) are smoked. This procedure is predicted to accomplish three goals: 1) the rewarding effects of CC will be disrupted because subjects will already have attained fairly high peak nicotine concentrations immediately before smoking the cigarette. This reduces the rewarding effect of smoking, in part from receptor desensitization that occurs following nicotine exposure, which reduces the response to a subsequent dose of nicotine, and in part from satiating the drive to smoke; 2) the use of the JUUL will become associated with the same cues that elicit smoking, thereby promoting the substitution of JUUL use for CC use; and 3) ad libitum nicotine intake from the JUUL and its rewarding effects will be maximized because, unlike CC, they will be experienced after a period of nicotine deprivation. Thus, despite a lower per-puff nicotine dose relative to CC, the pharmacologic impact and reinforcing effect will be maximized. The study will evaluate two flavors (Mint and Virginia Tobacco), randomly assigned, to determine if flavor assignment (similar to the subjects' usual brand of CC or different than the subjects usual brand CC) has an effect on the success of this reconditioning procedure.

Conditions

Smoking Cessation; Harm Reduction; E-Cig Use; Cigarette Smoking; Tobacco Dependence; Tobacco Use Cessation

Outcome Measures

Primary Outcomes (1)

• Effects of Devaluation on Switching From Cigarettes to the JUUL E-cigarette

  Biochemically verified smoking abstinence during weeks 9-12, i.e., self-report of no smoking confirmed by an expired air CO reading of \<5 ppm.

  During Weeks 9-12

Secondary Outcomes (1)

• Changes in Cigarette Reward With Subsequent Switching Behavior

  Week 1

Study Arms (2)

e-Cigarette Matched to Usual Brand Cigarette

EXPERIMENTAL

JUUL and cigarette flavor matched ("Mint" for menthol smokers and "Virginia Tobacco" for non-menthol smokers);

Other: JUUL

e-Cigarette Unmatched to Usual Brand Cigarette

EXPERIMENTAL

JUUL and cigarette flavor unmatched ("Virginia Tobacco" for menthol smokers and "Mint" for non-menthol smokers).

Other: JUUL

Interventions

JUUL OTHER

Subjects will be instructed to use the JUUL as often as they like during the 12-week product use period. They will also be instructed to use JUUL immediately before each cigarette to relieve their craving as much as possible before smoking their usual brand. The JUUL will also be the first product that they are instructed to use each morning. Smokers will be told to try to completely substitute JUUL for cigarettes by the end of the first week of use.

e-Cigarette Matched to Usual Brand Cigarette; e-Cigarette Unmatched to Usual Brand Cigarette

Eligibility Criteria

• Age: 21 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Has signed the ICF and is able to understand the information provided in the ICF.
• Is 21 to 65 years of age (inclusive) at screening.
• Smokes ≥ 10 commercially available CCs per day (no brand restrictions), for the last 12 months.
• Expired air CO reading of at least 10 ppm as assessed at the screening session.
• Interested in switching to an electronic cigarette.
• Willing and able to comply with the requirements of the study.
• Owns a smartphone with text message and data capabilities compatible with necessary surveys.

You may not qualify if:

• Is unhealthy or cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason) as judged by the Investigator or designated medical staff based on all available assessments from the screening period (e.g., safety laboratory, vital signs, physical examination, ECG, concomitant medications and medical history).
• PHQ-9 score greater than 9, or a score greater than 0 on item #9 ("Thoughts that you would be better off dead, or of hurting yourself in some way") at screening.
• Planned use of an FDA-approved smoking cessation product during the study.
• High Blood Pressure (systolic \>150 mm Hg, diastolic \>95 mm Hg) at screening.
• Body mass index (BMI) less than 15.0 kg/m2 or greater than 40.0 kg/m2.
• Coronary heart disease, structural cardiac disease (including, but not limited to valvular heart disease or cardiac murmurs), cardiac dysrhythmias, syncope, cardiac chest pain, or history of heart attack or heart failure.
• Has received psychotherapy or behavioral treatments within 30 days of screening, or during the study.
• Taking antidepressants or psychoactive medications (e.g. antipsychotics, benzodiazepines, hypnotics).
• Use of any of these products in the past 30 days:
• Illegal drugs (or if the urine drug screen is positive for cocaine, THC, amphetamines, methamphetamines, or opiates);
• Experimental (investigational) drugs that are unknown to the subject;
• Chronic opiate use.
• Use of smokeless tobacco (chewing tobacco, snuff), cigars (except for "Black \& Mild" cigars or Cigarillos), pipes, hookah, e-cigarettes, nicotine replacement therapy or other smoking cessation treatments within 14 days of screening.
• Pregnant or nursing (by self-report) or positive pregnancy test.

Sponsors & Collaborators

• Rose Research Center, LLC: lead
• Foundation for a Smoke Free World INC: collaborator

Study Sites (2)

Rose Research Center

Charlotte, North Carolina, 28262, United States

Location

Rose Research Center

Raleigh, North Carolina, 27617, United States

Location

MeSH Terms

Conditions

Smoking Cessation; Harm Reduction; Vaping; Cigarette Smoking; Tobacco Use Disorder; Tobacco Use Cessation

Condition Hierarchy (Ancestors)

Health Behavior; Behavior; Smoking; Tobacco Smoking; Tobacco Use; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders

Results Point of Contact

• Title: Dr. Jed E. Rose
• Organization: Rose Research Center

jed.rose@roseresearchcenter.com

9193282345

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: President and CEO

Study Record Dates

• First Submitted: September 9, 2019
• First Posted: December 5, 2019
• Study Start: August 26, 2019
• Primary Completion: March 2, 2021
• Study Completion: June 22, 2021
• Last Updated: April 20, 2025
• Results First Posted: April 20, 2025

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (2)